Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: A randomized trial

European Journal of Endocrinology

Volumn 165, Issue 2, 2011, Pages 293-300

  Christiansen, Jens J ^a   Bruun, Jens M ^a   Christiansen, Jens S ^a   Jørgensen, Jens Otto ^a   Gravholt, Claus H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; CALCIUM; ESTRADIOL; FLUDROCORTISONE; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; CORTICOSTEROID;

ABDOMINAL FAT; ADIPOSE TISSUE; ADRENAL CORTEX INSUFFICIENCY; ADULT; ANDROGEN THERAPY; ANXIETY; ARTICLE; BICYCLE ERGOMETRY; BODY COMPOSITION; BODY FAT DISTRIBUTION; BONE METABOLISM; BONE MINERAL; CALORIMETRY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY METABOLISM; FEMALE; FEMALE FERTILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LEAN BODY WEIGHT; MORNING DOSAGE; MUSCLE BIOPSY; MUSCLE FUNCTION; MUSCLE TISSUE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEBORRHEA; SELF REPORT; SIDE EFFECT; TREATMENT DURATION; ADRENAL INSUFFICIENCY; BONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HORMONE SUBSTITUTION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; TIME; ANTHROPOMETRY; BODY MASS; DRUG SAFETY;

ADRENAL CORTEX HORMONES; ADRENAL INSUFFICIENCY; ADULT; BODY COMPOSITION; BONE AND BONES; CROSS-OVER STUDIES; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MUSCLE, SKELETAL; PLACEBOS; TIME FACTORS;

EID: 79960182980     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0289     Document Type: Article

References (35)

1. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI & Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Annals of Internal Medicine 1987 106 354-361. (Pubitemid 17029484)
2. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ & Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. Journal of Clinical Endocrinology and Metabolism 1996 81 4358-4365. (doi:10.1210/jc.81.12. 4358)
3. Sheffield-Moore M. Androgens and the control of skeletal muscle protein synthesis. Annals of Medicine 2000 32 181-186. (doi:10.3109/07853890008998825)
4. Davidson JM, Camargo CA & Smith ER. Effects of androgen on sexual behavior in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1979 48 955-958. (doi:10.1210/jcem-48-6-955)
5. Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS & Jorgensen JO. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology 2005 152 719-726. (doi:10.1530/eje.1.01898)
6. Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S & Klibanski A. Androgen deficiency in women with hypopituitarism. Journal of Clinical Endocrinology and Metabolism 2001 86 561-567. (doi:10.1210/jc.86.2.561)
7. Young J, Couzinet B, Nahoul K, Brailly S, Chanson P, Baulieu EE & Schaison G. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. Journal of Clinical Endocrinology and Metabolism 1997 82 2578-2585. (doi:10.1210/jc.82.8.2578)
8. Christiansen JJ, Gravholt CH, Fisker S, Svenstrup B, Bennett P, Veldhuis J, Andersen M, Christiansen JS & Jorgensen JO. Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters. Clinical Endocrinology 2004 60 461-469. (doi:10.1111/j.1365-2265.2004.01998.x)
9. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM & Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency [see comments]. New England Journal of Medicine 1999 341 1013-1020. (doi:10.1056/NEJM199909303411401)
10. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JAH, Herbert J & Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism 2000 85 4650-4656. (doi:10.1210/jc.85.12.4650)
11. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA & Karlsson FA. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2002 87 2046-2052. (doi:10.1210/jc.87.5.2046)
12. Brooke AM, Kalingag LA, Miraki-Moud F, Camacho-Hubner C, Maher KT, Walker DM, Hinson JP & Monson JP. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. Journal of Clinical Endocrinology and Metabolism 2006 91 3773-3779. (doi:10.1210/jc.2006-0316)
13. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, Myking OL, Kampe O & Husebye ES. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. Journal of Clinical Endocrinology and Metabolism 2003 88 1112-1118. (doi:10.1210/jc.2002-020769)
14. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J & Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 2008 93 400-409. (doi:10.1210/jc.2007- 1134)
15. van Thiel SW, Romijn JA, Pereira AM, Biermasz NR, Roelfsema F, van Hemert A, Ballieux B & Smit JW. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. Journal of Clinical Endocrinology and Metabolism 2005 90 3295-3303. (doi:10.1210/jc.2004-1802)
16. Christiansen JJ, Andersen NH, Sorensen KE, Pedersen EM, Bennett P, Andersen M, Christiansen JS, Jorgensen JO & Gravholt CH. Dehydroepiandrosterone substitution in female adrenal failure: no impact on endothelial function and cardiovascular parameters despite normalization of androgen status. Clinical Endocrinology 2007 66 426-433. (doi:10.1111/j.1365- 2265.2007.02750.x)
17. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. Journal of Applied Physiology 1983 55 628-634. (Pubitemid 13044099)
18. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S & Svenstrup B. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clinical Endocrinology 1985 23 385-393. (doi:10.1111/j.1365-2265.1985.tb01096.x)
19. Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas 1980 2 109-118. (doi:10.1016/0378-5122(80)90044-4)
20. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR & Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. Journal of Bone and Mineral Research 1992 7 1251-1258. (doi:10.1002/jbmr.5650071119)
21. Rosalki SB, Foo AY, Burlina A, Prellwitz W, Stieber P, Neumeier D, Klein G, Poppe WA & Bodenmuller H. Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. Clinical Chemistry 1993 39 648-652. (Pubitemid 23118316)
22. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A & Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clinical Chemistry 1996 42 947-954.
23. Risteli J, Sogaard H, Oikarinen A, Risteli L, Karvonen J & Zachariae H. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. British Journal of Dermatology 1988 119 321-325. (doi:10.1111/j.1365-2133.1988.tb03224.x)
24. Risteli J, Elomaa I, Niemi S, Novamo A & Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clinical Chemistry 1993 39 635-640. (Pubitemid 23118314)
25. Frystyk J, Dinesen B & Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation 1995 5 169-176. (Pubitemid 26018330)
26. Weeke J, Boye N & Orskov H. Ultrafiltration method for direct radioimmunoassay measurement of free thyroxine and free tri-iodothyronine in serum. Scandinavian Journal of Clinical and Laboratory Investigation 1986 46 381-389. (doi:10.3109/00365518609083686)
27. Webb SJ, Geoghegan TE, Prough RA & Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metabolism Reviews 2006 38 89-116. (doi:10.1080/03602530600569877)
28. Sun H, Zang W, Zhou B, Xu L & Wu S. DHEA suppresses longitudinal bone growth by acting directly at growth plate through estrogen receptors. Endocrinology 2011 152 1423. (doi:10.1210/en.2010-0920)
29. Labrie F. Intracrinology. Molecular and Cellular Endocrinology 1991 78 C113-C118. (doi:10.1016/0303-7207(91)90116-A)
30. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W & Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. Journal of Clinical Endocrinology and Metabolism 2001 86 1968-1972. (doi:10.1210/jc.86.5.1968)
31. Christiansen JJ, Gravholt CH, Fisker S, Moller N, Andersen M, Svenstrup B, Bennett P, Ivarsen P, Christiansen JS & Jorgensen JO. Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism. European Journal of Endocrinology 2005 152 77-85. (doi:10.1530/eje.1.01810)
32. Burt MG, Johannsson G, Umpleby AM, Chisholm DJ & Ho KK. Impact of growth hormone and dehydroepiandrosterone on protein metabolism in glucocorticoid-treated patients. Journal of Clinical Endocrinology and Metabolism 2008 93 688-695. (doi:10.1210/jc.2007-2333)
33. Dhatariya K, Bigelow ML & Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 2005 54 765-769. (doi:10.2337/diabetes.54.3.765)
34. Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO & Christiansen JS. Short term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity. A randomized double-blind, placebo-controlled cross-over study. Pediatrics 2002 110 889-896. (doi:10.1542/peds.110.5.889)
35. Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C & Partington C. Exogenous androgens influence body composition and regional body fat distribution in obese post-menopausal women - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2198-2203. (doi:10.1210/jc.81.6.2198)